Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Stivarga

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    - PMLiVE

    BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

    Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    - PMLiVE

    AstraZeneca shares ‘unprecedented’ survival results for Imfinzi/Imjudo regimen in liver cancer

    Almost 900,000 new cases of liver cancer are diagnosed globally every year

    Bayer symbol

    Bayer presents positive results for Kerendia in late-stage heart failure study

    Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

    Bayer symbol

    Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

    The companies will advance small molecule therapeutics against a new class of targets for cancer

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links